arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Invivyd, Inc.

IVVD
$0.74 ▲ +0.09 (+13.55%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
24 Visible periods
24 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Bearish
auto_awesome

Analytical Summary

Invivyd, Inc. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $229.2M
Dividend Yield
Revenue Growth 21.6%
Op. Margin -313.9%
ROIC -16.8%
FCF / Share $-0.14
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

24-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$13.74M
↑ +21.6%
Net Income Profit after all expenses
$-41.40M
↓ -154.2%
Operating Margin Operating profit as % of sales
-313.9%
↓ -330.1% 2th
FCF / Share Free cash flow per share
$-0.14
↑ +22.8%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
27
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 6 years · 24 quarters